Basal cell carcinoma (BCC) is the most common type of skin cancer, accounting for roughly 80% of all non-melanoma skin cancers. An estimated 4.3 million cases are diagnosed each year in the United States alone. Despite those numbers, BCC is slow-growing, rarely spreads to other parts of the body, and is highly curable when caught early.
Where It Starts in the Skin
BCC develops from basal cells, small round cells that sit in the lowest layer of the epidermis, the outermost part of your skin. These cells are pluripotential, meaning they continuously divide throughout your life and can develop into hair follicles, oil glands, and sweat glands. Sometimes a tumor originates not from the flat surface of the skin but from the outer root sheath of a hair follicle, specifically from stem cells in a region just below the oil gland called the bulge.
The key driver behind most BCCs is a malfunction in a cellular communication system called the Hedgehog signaling pathway. Normally, this pathway is kept in check by a protein that acts like a brake on cell growth. When the gene coding for that protein mutates, the brake releases and cells receive a constant “grow” signal they can’t shut off. Most basal cell carcinomas have a defect somewhere in this pathway, and some researchers consider it a requirement for BCC to develop at all.
What It Looks Like
BCC doesn’t have a single appearance. It comes in several subtypes, each with a distinct look and behavior.
Nodular BCC
This is the most common form, making up more than 60% of all cases. It typically appears as a round, pearly, flesh-colored bump with tiny visible blood vessels running across its surface. As the bump grows, the center often breaks down into an open sore while the edges remain raised and shiny. Those fine blood vessels can bleed easily, which is sometimes the first thing people notice.
Superficial BCC
Superficial BCC looks like a flat, pink, scaly patch on the skin. It’s frequently misdiagnosed as eczema or psoriasis because it can look so similar. One distinguishing feature is the absence of thick, white, flaky scale, and the lesion tends to persist unchanged for months or even years rather than flaring and fading the way a rash would.
Morpheaform BCC
This less common variant, accounting for about 10% of cases, looks like a flat or slightly sunken white or yellowish waxy patch that resembles a scar. It rarely forms an open sore. Because it doesn’t look like a typical skin cancer, it can go unrecognized longer than other types, giving it more time to extend beneath the surface.
Micronodular BCC
This aggressive subtype can appear to have a well-defined border, which is deceptive. It feels firm, may look yellow-white when the skin is stretched, and doesn’t tend to ulcerate. Its borders often extend farther than what’s visible, making complete removal more challenging.
Risk Factors
Cumulative ultraviolet (UV) exposure is the primary risk factor. Years of sun exposure, frequent sunburns, and tanning bed use all increase your likelihood. BCC most commonly appears on sun-exposed areas: the face, ears, neck, scalp, and shoulders. Fair skin, light eyes, and a tendency to burn rather than tan raise the risk further. A personal or family history of any skin cancer also makes a new BCC more likely.
How It’s Diagnosed
A dermatologist can often suspect BCC based on appearance alone, but confirmation requires a biopsy. This is a quick in-office procedure where a small sample of the suspicious spot is removed and examined under a microscope. The biopsy also identifies the subtype, which matters because different subtypes call for different treatment approaches.
Treatment Options
Surgery is the standard treatment for most BCCs, and cure rates are high. Two main surgical approaches dominate. Standard surgical excision removes the visible tumor along with a margin of normal-looking skin around it. Mohs micrographic surgery is a more precise technique where thin layers of tissue are removed one at a time and examined under a microscope during the procedure, continuing until no cancer cells remain at the edges. A randomized trial comparing the two methods for facial BCC found recurrence rates of about 4% for standard excision and 2.5% for Mohs surgery after five years of follow-up, a difference that was not statistically significant for primary tumors. Mohs is generally reserved for BCCs in cosmetically sensitive areas like the nose, eyelids, and ears, or for aggressive subtypes where preserving healthy tissue matters most.
For superficial BCC, non-surgical options exist. Topical creams that stimulate the immune system or interfere with abnormal cell growth can be applied at home over several weeks. A five-year clinical trial involving 601 patients compared three non-surgical treatments for superficial BCC. The immune-stimulating cream performed best, with about 80.5% of patients remaining tumor-free at five years. A chemotherapy cream came in at 70%, and a light-based therapy called photodynamic therapy at roughly 63%. These numbers are lower than surgery, so topical treatments are typically reserved for low-risk superficial lesions where surgery would be impractical or overly invasive.
For the rare cases where BCC grows too large for surgery or appears in a location where surgery isn’t feasible, targeted oral medications can block the overactive Hedgehog signaling pathway driving the tumor’s growth. These drugs are considered first-line treatment for advanced BCC and can achieve lasting responses. Immunotherapy is generally held in reserve for patients whose tumors develop resistance to those targeted drugs or who can’t tolerate the side effects.
How Serious Is It?
BCC is the least dangerous form of skin cancer. It grows slowly and almost never spreads to distant organs. Metastasis is extraordinarily rare, estimated at well under 1% of cases. The real risk with BCC isn’t that it will spread through your body but that it will keep growing locally, potentially invading deeper tissue, cartilage, or bone if ignored for years. Tumors on the face, particularly near the eyes, nose, or ears, can cause significant damage if left untreated.
Exact mortality numbers are hard to pin down because, unlike most other cancers, basal and squamous cell skin cancers aren’t tracked by cancer registries in the United States. The vast majority of deaths from BCC occur in advanced cases that went untreated for a long time.
Recurrence and Long-Term Monitoring
Having one BCC means you’re at higher risk for developing another. This isn’t necessarily a recurrence of the original tumor but rather a new one forming elsewhere. Most true recurrences show up within three to five years of the original diagnosis. Regular skin checks with a dermatologist are the most effective way to catch new or recurring lesions early, when treatment is simplest and outcomes are best. Many dermatologists recommend visits every six to twelve months for the first few years, then annually after that.
Sun protection becomes especially important after a BCC diagnosis. Daily broad-spectrum sunscreen, protective clothing, and avoiding peak UV hours won’t erase past damage, but they meaningfully reduce the chance of new tumors forming on already vulnerable skin.